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(MMRM). Pearson correlations examined the associations
between sexual dysfunction, medication adherence and indica-
tors of well-being. RESULTS: Compared to risperidone-treated
patients, those treated with olanzapine reported signiﬁcantly
greater long-term improvements in medication-related sexual
dysfunction (p < 0.001). Greater sexual dysfunction was signif-
icantly (p < 0.05) associated with greater emotional distress,
poorer mental functioning, lower life satisfaction, less satisfac-
tion with social life, and poorer self-reported medication 
adherence. CONCLUSION: Treatment with risperidone was
associated with greater sexual dysfunction compared to olanza-
pine. Findings suggest that minimizing treatment-related sexual
dysfunction may decrease emotional distress, improve life satis-
faction, and increase adherence with medication.
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OBJECTIVES: This study examined whether remission of psy-
chotic symptoms is associated with favorable long-term func-
tional and health-related quality of life (HRQOL) outcomes 
in the treatment of schizophrenia patients in usual care.
METHODS: We used data from the United States Schizophre-
nia Care and Assessment Program (SCAP), a 3-year observa-
tional study of schizophrenia, in which participants were
assessed at enrollment and 12-month intervals. Remission of psy-
chotic symptoms was deﬁned using the Remission in Schizo-
phrenia Working Group expert consensus criteria. Functional
and HRQOL outcomes were assessed with validated measures.
Four patient groups were compared on long-term outcomes: con-
tinuously remitted patients (R Æ R, N = 229); continuously non-
remitted patients (NR Æ NR, N = 1110); patients who changed
from non-remitted to remitted and stayed remitted (NR Æ R, 
N = 234); and patients who changed from remitted to non-
remitted and stayed non-remitted (R Æ NR, N = 202). Analysis
employed Generalized Estimating Equation (GEE) and mixed
models with repeated-measures. RESULTS: The R Æ R group
had signiﬁcantly better outcomes than the NR Æ NR and R Æ
NR groups on measures of productivity and occupational func-
tioning, social activity, daily activity, Global Assessment of Func-
tioning (GAF), mental health, quality of life, and life satisfaction.
The NR Æ R group did not signiﬁcantly differ from the R Æ R
group on most measures, but had signiﬁcantly poorer quality of
life, daily activity, GAF, and occupational functioning. CON-
CLUSIONS: In this large prospective naturalistic study, remis-
sion of psychotic symptoms was associated with a broad range
of favorable long-term functional and HRQOL outcomes. Find-
ings highlight the importance of achieving and maintaining
symptomatic remission in the long-term treatment of schizo-
phrenia patients in usual practice settings.
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OBJECTIVES: To explore the feasibility of estimating a prefer-
ence based utility score for the SQLS-R4 by mapping it onto the
utility scores generated from the published SF-6D and EQ-5D
tariffs. METHODS: The study consisted of a sample of 156
people with schizophrenia who completed the SQLS-R4, EQ-5D
and the SF-36. To facilitate regression modelling both sets of
scores were subtracted from unity to give utility decrement on
the scale zero to positive inﬁnite. In the regression models the
utility decrements were entered as dependent variables with the
three levels of SQLS-R4 data [total score, domain scores, indi-
vidual items scores] acting as explanatory variables. For each of
the levels two models were considered each for the EQ-5D and
SF-6D, the standard OLS model and a gamma distribution GLM
with the canonical log link. RESULTS: For both the EQ-5D and
SF-6D models as the number of explanatory variables increased
so did the variance explained by the data (R2), with a gradual
steady increase for the SF-6D, compared to a much sharper
increase from 43% to 55% for the EQ-5D. AICs were used to
provide a comparison between the OLS models and the GLMs.
For all 3 levels of SQLS-R4 explanatory variables the GLM
(gamma/log) was preferred over the OLS model for the EQ-5D
data, with the opposite being true for the SF-6D. CONCLU-
SIONS: There was little to choose between the 3 levels of models,
with the exception that much more variance was accounted for
by inclusion of all the items compared to the domain scores for
the EQ-5D OLS model. However, caution should be taken when
selecting which model to use, as the EQ-5D GLM model resulted
in higher utility scores than the SF-6D OLS model for patients
with good quality of life, whereas the opposite was true for
patients with poor quality of life.
PMH46
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OBJECTIVES: Neurocognitive deﬁcits were shown to be associ-
ated with poorer functional outcomes. This study examines if
changes in cognitive deﬁcits are linked to changes in functional
outcomes in the long-term treatment of schizophrenia patients
in usual care, and whether this link is independent of changes in
EPS, Positive and Negative symptoms. METHOD: Participants
were 2144 patients who completed at least 1-year follow up in
the U.S. Schizophrenia Care and Assessment Program, a 3-year
observational study of patients with schizophrenia. Cognitive
impairment was assessed by the PANSS Cognitive Factor (PANSS
Cog). Functional outcomes were measured by the Quality of Life
Scale (QLS), the Global Assessment of Functioning Scale (GAF),
and the SCAP-Health Questionnaire (SCAP-HQ). Changes were
measured from baseline to the end of 1-year follow-up. Statisti-
cal analysis employed Pearson correlations, path analyses, 
and generalized linear models. RESULTS: Improvements in the
PANSS Cog were signiﬁcantly correlated with improvements in
occupational role functioning, social functioning, capacity to
engage in activities, participation in the community, GAF, daily
activities, employment status, and hourly wages. When adjust-
ing for EPS, Positive and Negative symptoms, cognitive improve-
ments were signiﬁcantly (p < 0.05) associated with improved
GAF, QLS total score, occupational role functioning, and hourly
wages. CONCLUSION: Improvements in cognitive deﬁcits
appear to be associated with improved functional outcomes.
Since the PANSS Cognitive Factor was used as a proxy measure
of cognition, current ﬁndings will require replications with neu-
ropsychological tests. Findings suggest that improving cognitive
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functioning may become one of the most important clinical
targets in the treatment of schizophrenia.
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OBJECTIVE: To investigate if a) the previously observed link
between weight gain and better clinical response during treat-
ment of schizophrenia has a non-pharmacological component,
and b) if the magnitude of treatment-related weight gain paral-
lels therapeutic effect size across different treatments.
METHODS: We compared olanzapine (N = 187) and placebo
(N = 61) during the ﬁrst 6 weeks of a randomized double-blind
trial in the treatment of schizophrenia. Pearson correlations
assessed the association between weight change and therapeutic
response as measured by BPRS total score. Weight change within
treatment group was contrasted between patients who improved
and those who deteriorated. Analyses were repeated controlling
for treatment duration and baseline weight. RESULTS: Weight
gain was signiﬁcantly correlated with better therapeutic response
for placebo (r = 0.36, p = 0.004) and olanzapine-treated patients
(r = 0.43, p = 0.001). Improved patients gained signiﬁcantly more
weight than patients who deteriorated (p = 0.0001). After 
controlling for treatment duration and baseline weight, every 
1-point improvement on BPRS was associated with 0.056kg
weight gain for olanzapine and 0.089kg weight gain for placebo.
The correlation between therapeutic effect size, per Cochrane’s
meta-analytical reviews, and previously published magnitude of
the corresponding treatment’s weight gain (clozapine, olanzap-
ine, risperidone, haloperidol, placebo) was high and signiﬁcant
(r = 0.91, p = 0.03). CONCLUSIONS: An association between
improvement in psychopathology and greater weight gain was
observed in schizophrenia patients treated with olanzapine and
placebo. Findings suggest that treatment-related weight gain has,
in part, a non-pharmacological basis. Further studies are needed
to evaluate the hypothesis that weight gain, regardless of treat-
ment, is associated with improving psychopathology in schizo-
phrenia patients.
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OBJECTIVES: Evaluation of HRQOL has gained increasing
importance in assessing the impact of mental health policies and
the introduction of new neuroleptic drugs. Quetiapine, a new
antipsychotic medication with improved effectiveness, safety and
tolerability proﬁle was introduced in Greece in 2001. The objec-
tive of this study is to assess the HRQOL impact of quetiapine-
based treatment to patients with schizophrenia using a combined
set of outcome measures based on a) psychopathology, b)
HRQOL proﬁles and c) disability scales. METHODS: An open
label, 52-week follow–up study of 170 patients is being con-
ducted in 8 psychiatric hospitals across Greece. Enrolled patients
were diagnosed with mild to moderate schizophrenia (according
to the DSM-IV), aged 18–65, hospitalized or outpatients, newly
diagnosed or in acute exacerbation and assessed at 4 scheduled
visits (baseline, 3-6-12 months). Outcome measures employed
combine psychopathology scales (PANSS, CGI), HRQOL pro-
ﬁles (SF-36, EQ-5D, QLS) and disability indices (WHO-DAS).
All measures are psychometrically and culturally adapted. The
results of 6-month follow-up period are presented in this analy-
sis. RESULTS: Compared to baseline, statistically signiﬁcant
improvements were seen at 6 months in PANSS general psy-
chopathology (48.6 vs. 33.3), positive (23.8 vs.15.2) and nega-
tive symptom (24.3 vs. 17.8) mean scores (p < 0.001). CGI scores
improved from mean level of 5,1 (baseline) to 4,1 (p < 0.001).
All SF-36 dimension scores, especially Role Physical and Role
Emotional were signiﬁcantly improved (p < 0.001). All EQ-5D
dimensions were improved but only the mobility dimension 
and VAS scores showed statistically signiﬁcant improvement 
(p < 0.001). Total and subscale QLS scores were signiﬁcantly
improved except the Instrumental Role Subscale Score (p <
0.001). A statistically signiﬁcant improvement was shown on all
WHO-DAS-II dimensions (p < 0.001). CONCLUSIONS: After
6 months follow-up, quetiapine-treated patients showed a con-
siderable, signiﬁcant improvement in terms of psychopathology
and HRQOL. The combined approach provides for a compre-
hensive assessment of HRQOL impact of new antipsychotic
medications.
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OBJECTIVES: Since end-users of surveys may have design
format preferences that are undetected by survey
developer/administrators, we elicited client and staff input and
preferences for three survey formats of a 51-item health-related
quality of life survey for community-residing individuals with
schizophrenia. METHODS: Using cognitive interviews and
visual analogue preference ratings (0–100 scale), we sought 
qualitative and quantitative input from 29 community-residing
clients with schizophrenia and 33 staff members at four sites con-
cerning their preferences for three formats of the 51-item Schiz-
ophrenia Outcomes Assessment Project (SOAP-51) Survey: (i)
6-page booklet with reponses horizontally listed below each
item, (ii) 4-page version with reponses to the right of each item,
and (iii) compressed 2-page version of the former. Survey formats
were presented in randomized order. Staff alsowere asked their
preference for a 4 vs 5 response format. Clients were individu-
ally interviewed in 15–20 minute sessions; staff had individual
(20–30 minute) or group (45–60 minute) sessions. RESULTS:
Clients preferred versions (i) and (ii) over version (iii); respective
VAS values of 70.1, 68.9, and 47.0 (p = 0.012). Qualitatively,
clients indicated the 2-page was too compressed and the 4-page
format made it easier to link the response to the question. Staff
preferred 4/item responses to 5 (84.0 vs 46.1, p < 0.0001)
because they perceived little distinction between 2 of the 5
response levels. Staff had a preference trend toward version (ii)
compared to versions (i) and (iii), 68.6, 58.6, and 58.9, respec-
tively, p = 0.22. When asked their ﬁrst choice, 47%, 34%, and
19% indicated preference for 4-page, 2-page, and booklet ver-
sions, respectively. CONCLUSIONS: Clients preferred booklet
